Haploidentical Donor vs mMUD in Hematological Malignancies

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

April 13, 2024

Study Completion Date

April 13, 2024

Conditions
AMLALLMDS
Interventions
BIOLOGICAL

Peripheral blood stem cells

Hematopoietic stem cell transplantation with PBSC

Trial Locations (9)

48149

Universitätsklinikum Münster, Münster

53105

Universitätsklinikum Bonn, Bonn

60595

Universitätsklinikum Frankfurt, Frankfurt am Main

68167

Universitätsmedizin Mannheim, Mannheim

70376

Robert-Bosch-Krankenhaus, Stuttgart

72076

Universitätsklinikum Tübingen, Tübingen

90419

Klinikum Nürnberg Nord, Nuremberg

Unknown

Universitätsklinikum Dresden, Dresden

06120

Universitätsklinikum Halle (Saale), Halle

All Listed Sponsors
lead

DKMS gemeinnützige GmbH

OTHER

NCT03275636 - Haploidentical Donor vs mMUD in Hematological Malignancies | Biotech Hunter | Biotech Hunter